AS-GSH CONJUGATION LIMITS AS AVAILABILITY & TOXICITY

AS-GSH 结合限制了可用性

基本信息

  • 批准号:
    6087177
  • 负责人:
  • 金额:
    $ 29.88万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2000
  • 资助国家:
    美国
  • 起止时间:
    2000-06-05 至 2005-05-31
  • 项目状态:
    已结题

项目摘要

The overall goal of this work is to learn more about the detoxification and clearance of arsenic (As) and to examine the role that As-protein conjugates play in toxicity. The major hypothesis to be tested is that clearance of As in vivo is dependent on two separate pathways, a major one involving formation and transport of As-GSH conjugates and a minor one dependent on transport of As ions; further, failure to reduce the reactivity of As b GSH conjugation allows the formation of metal-protein thiols that are toxic to the cell. The project takes advantage of recent advances in mass spectrometry and molecular genetics to address these issues. Although it is widely postulated that GSH conjugates of As are essential for its detoxification, there is no convincing demonstration of their existence in vivo. The investigators have synthesized arsenic triglutathione (ATG) and methyl arsenic diglutathione (MADG) and identified them in the urine of gamma-glutamyl transpeptidase (GGT)-deficient mice and the bile of wild type mice by use of liquid chromatography/mass spec (LCMS) and LC/inductive coupled MS (LC/ICP-MS). Other preliminary data using multidrug resistance-associated protein 2 (MRP2)-deficient rats have shown that As excretion into bile is dependent on this gene. They have also used gamma-glutamyl cysteine synthetase (GGCS)-deficient embryos to develop cells that lack the ability to synthesize GSH and demonstrated that these cells are As-sensitive. They will extend these studies and develop methods to study other As-thiol conjugates in vivo. They will test the hypothesis that formation of As-GSH conjugates and their As-cysteine derivatives are quantitatively the most important pathway in As clearance. They will use rodents deficient in MDR proteins and MRPs to test the hypothesis that these proteins function in As-GSH excretion. They have determined that yeast deficient in the ubiquitin/proteasome pathway for protein degradation is sensitive to As. They will use these, GGCS-deficient and GSH-overproducing mammalian cells, and mice deficient in ubiquitin/proteasome function to test the hypothesis that failure to form As-GSH conjugates allows formation of As-protein thiol conjugates that are toxic to the cell.
这项工作的总体目标是了解更多关于排毒 和砷(As)的清除,并检查As蛋白的作用, 结合物在毒性中起作用。有待检验的主要假设是, 体内As的清除依赖于两个独立的途径,一个主要的途径 包括As-GSH结合物的形成和转运, 依赖于As离子的运输;此外,未能降低 由于B GSH结合允许形成金属-蛋白硫醇, 对细胞有毒。该项目利用了最新的进展, 光谱和分子遗传学来解决这些问题。虽然 普遍认为,谷胱甘肽共轭物的砷是必不可少的, 解毒,没有令人信服的证据表明它们的存在, vivo.研究人员已经合成了砷三谷胱甘肽(ATG), 甲基砷二谷氨酸(MADG),并确定了他们的尿液中, γ-谷氨酰转肽酶(GGT)缺陷型小鼠和野生型胆汁 通过使用液相色谱/质谱(LCMS)和LC/电感耦合 MS(LC/ICP-MS)。使用多药耐药相关的其他初步数据 蛋白2(MRP 2)缺乏的大鼠已经表明, 依赖于这个基因。他们还使用了γ-谷氨酰半胱氨酸合成酶 (GGCS)缺陷胚胎发育细胞缺乏合成能力, GSH,并证明这些细胞是As敏感的。他们会把这些 研究和开发方法,以研究其他砷-巯基结合物在体内。他们 将检验As-GSH结合物的形成及其 As-半胱氨酸衍生物在数量上是As中最重要的途径 间隙他们将使用缺乏MDR蛋白和MRP的啮齿动物来测试 假设这些蛋白质在As-GSH排泄中起作用。他们有 确定酵母缺乏蛋白质的泛素/蛋白酶体途径, 降解对As敏感。他们将使用这些,GGCS缺陷, GSH过量产生的哺乳动物细胞和泛素/蛋白酶体缺陷的小鼠 功能,以检验未能形成As-GSH结合物允许 形成对细胞有毒的As-蛋白巯基缀合物。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Michael Lieberman其他文献

Michael Lieberman的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Michael Lieberman', 18)}}的其他基金

Baylor College of Medicine Cancer Center
贝勒医学院癌症中心
  • 批准号:
    6698888
  • 财政年份:
    2003
  • 资助金额:
    $ 29.88万
  • 项目类别:
AS-GSH CONJUGATION LIMITS AS AVAILABILITY & TOXICITY
AS-GSH 结合限制了可用性
  • 批准号:
    6751962
  • 财政年份:
    2000
  • 资助金额:
    $ 29.88万
  • 项目类别:
AS-GSH CONJUGATION LIMITS AS AVAILABILITY & TOXICITY
AS-GSH 结合限制了可用性
  • 批准号:
    6518175
  • 财政年份:
    2000
  • 资助金额:
    $ 29.88万
  • 项目类别:
AS-GSH CONJUGATION LIMITS AS AVAILABILITY & TOXICITY
AS-GSH 结合限制了可用性
  • 批准号:
    6635509
  • 财政年份:
    2000
  • 资助金额:
    $ 29.88万
  • 项目类别:
AS-GSH CONJUGATION LIMITS AS AVAILABILITY & TOXICITY
AS-GSH 结合限制了可用性
  • 批准号:
    6382356
  • 财政年份:
    2000
  • 资助金额:
    $ 29.88万
  • 项目类别:
RESPONSE TO INJURY IN GAMMAGLUTAMYL CYCLE DEFICIENT MICE
丙谷氨酰循环缺陷小鼠对损伤的反应
  • 批准号:
    6624932
  • 财政年份:
    1996
  • 资助金额:
    $ 29.88万
  • 项目类别:
FUNCTION OF GAMMA GLUTAMYL LEUKOTRIENASE
伽玛谷氨酰白三烯酶的功能
  • 批准号:
    6635474
  • 财政年份:
    1996
  • 资助金额:
    $ 29.88万
  • 项目类别:
RESPONSE TO INJURY IN GAMMAGLUTAMYL CYCLE DEFICIENT MICE
丙谷氨酰循环缺陷小鼠对损伤的反应
  • 批准号:
    6041314
  • 财政年份:
    1996
  • 资助金额:
    $ 29.88万
  • 项目类别:
FUNCTION OF GAMMA GLUTAMYL LEUKOTRIENASE
伽玛谷氨酰白三烯酶的功能
  • 批准号:
    6518108
  • 财政年份:
    1996
  • 资助金额:
    $ 29.88万
  • 项目类别:
METABOLISM IN GAMMA-GLUTAMY1 TRANSPEPTIDASE DEFICT MICE
GAMMA-GLUTAMY1 转肽酶缺陷小鼠的代谢
  • 批准号:
    2882839
  • 财政年份:
    1996
  • 资助金额:
    $ 29.88万
  • 项目类别:

相似海外基金

Metabolic impact of bile acid receptor in the brain
大脑中胆汁酸受体的代谢影响
  • 批准号:
    478006
  • 财政年份:
    2023
  • 资助金额:
    $ 29.88万
  • 项目类别:
    Operating Grants
Development of bile cell block specimens for enabling comprehensive genome profiling and therapeutic medicine discovery of bile tract cancer
开发胆细胞块样本,以实现胆道癌的全面基因组分析和治疗药物发现
  • 批准号:
    23K14646
  • 财政年份:
    2023
  • 资助金额:
    $ 29.88万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Bile acid-dependent T cell regulation in the intestine
肠道内胆汁酸依赖性 T 细胞调节
  • 批准号:
    10767546
  • 财政年份:
    2023
  • 资助金额:
    $ 29.88万
  • 项目类别:
Dietary prevention for colorectal cancer: targeting the bile acid/gut microbiome axis
结直肠癌的饮食预防:针对胆汁酸/肠道微生物组轴
  • 批准号:
    10723195
  • 财政年份:
    2023
  • 资助金额:
    $ 29.88万
  • 项目类别:
Primary cilia loss in bile duct cells- the interplay with the autophagy machinery
胆管细胞中初级纤毛的损失——与自噬机制的相互作用
  • 批准号:
    10605658
  • 财政年份:
    2023
  • 资助金额:
    $ 29.88万
  • 项目类别:
Glyphosate impairs glucose homeostasis via gut microbiome induced alterations to bile acid signaling
草甘膦通过肠道微生物组诱导的胆汁酸信号改变损害葡萄糖稳态
  • 批准号:
    10749326
  • 财政年份:
    2023
  • 资助金额:
    $ 29.88万
  • 项目类别:
Can circulating bile acids predict knee OA progression?
循环胆汁酸可以预测膝关节 OA 的进展吗?
  • 批准号:
    10575385
  • 财政年份:
    2023
  • 资助金额:
    $ 29.88万
  • 项目类别:
Roles for Pkd1l1 in bile duct development
Pkd1l1 在胆管发育中的作用
  • 批准号:
    10751883
  • 财政年份:
    2023
  • 资助金额:
    $ 29.88万
  • 项目类别:
Development of an in vitro liver culture system for continuous bile recovery
开发用于连续胆汁回收的体外肝脏培养系统
  • 批准号:
    23KJ0541
  • 财政年份:
    2023
  • 资助金额:
    $ 29.88万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Bile acid receptor signaling in retinopathy of prematurity
早产儿视网膜病变中胆汁酸受体信号传导
  • 批准号:
    10568100
  • 财政年份:
    2023
  • 资助金额:
    $ 29.88万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了